Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | Chief Technical Officer | August 01, 2022 | August 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date August 01, 2022 · Filed August 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2032-07-31 | Direct | 75,000 |
Reported balance
After 2022-08-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-01 · Grant · Acquired 75,000 · Balance 75,000 F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2022 Filed Aug 2, 2022 01:13 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0000899243-22-027270 · doc4.xml · derivative · entry 1 Nichols David Wayne · CIK 0001857488 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-07-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:20 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000899243-22-018807 · doc4.xml · derivative · entry 1 Nichols David Wayne · CIK 0001857488 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable in three equal installments, each installment vesting every six months, over the 18 months following the vesting commencement date. The vesting commencement date is May 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:18 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0000899243-22-006818 · doc4.xml · derivative · entry 1 Nichols David Wayne · CIK 0001857488 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 5,694 | $6.73 | $38,320.62 |
DisclosureSEC source: 0000899243-21-036595 · doc4.xml · nonDerivative · entry 1 Nichols David Wayne · CIK 0001857488 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,306 F1 · kind: This transaction represents shares sold solely to pay taxes due upon the vesting of restricted stock units, as disclosed by the reporting person on the Form 4 filed on September 16, 2021. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.87, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 23:39 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036333 · doc4.xml · nonDerivative · entry 1 Nichols David Wayne · CIK 0001857488 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: On April 19, 2021, the reporting person was granted 40,000 restricted stock units. The restricted stock units vest in two equal installments subject to the achievement of certain performance milestones related to the issuer's business plans. The first performance milestone was achieved, resulting in vesting of 20,000 restricted stock units and the corresponding issuance of 20,000 shares of issuer common stock. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 21:04 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $10.50 | $0.00 |
DisclosureSEC source: 0000899243-21-016411 · doc4.xml · derivative · entry 1 Nichols David Wayne · CIK 0001857488 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-04-18 F1 · derivative.exercise_date: This option shall vest and become exerciseable over four years, with 25% of this option vesting on April 19, 2021, and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 19, 2021 Filed May 17, 2021 21:07 UTC Amendment | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $10.50 | $0.00 |
DisclosureSEC source: 0000899243-21-019632 · doc4a.xml · derivative · entry 1 Nichols David Wayne · CIK 0001857488 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-04-18 F1 · derivative.exercise_date: This option shall vest and become exerciseable over four years, with 25% of this option vesting on April 19, 2022, and the remainder vesting in 36 equal monthly installments thereafter. F2 · derivative.exercise_date: This amendment has been filed to revise the vesting terms of Mr. Nichols' stock option, which were reported incorrectly on Mr. Nichols' prior Form 4. The corrected vesting schedule is included in Footnote 1 above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.